The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. 2004

Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
High Blood Pressure Research Unit, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia.

BACKGROUND Many forms of hypertension are associated with increased oxidative stress. This study investigated the effects of Tempol, a superoxide scavenger, on prevention and reversal of hypertension induced by the synthetic glucocorticoid dexamethasone (Dex) in the rat. METHODS Male Sprague-Dawley rats (n = 10 in each group) were treated with saline or Dex (10 microg/kg/day subcutaneously) for 13 days. Tempol (1 mmol/L) was given in drinking water from 4 days before treatment (prevention) or from treatment day 8 (T8) (reversal). Systolic blood pressure (SBP) was measured by the tail-cuff method. Plasma F(2)-isoprostane concentrations were measured as a highly specific marker of oxidative stress. Thymus weight was measured as a marker of glucocorticoid activity. RESULTS Dex treatment increased SBP (122 +/- 5 to 136 +/- 3 mm Hg, P <.05) and plasma F(2)-isoprostane concentrations (P =.005). Tempol alone did not alter SBP, but Tempol pretreatment prevented Dex-induced hypertension compared with that in rats treated with Dex alone (128 +/- 4 and 144 +/- 7 mm Hg respectively, P' <.05). Tempol partially reversed Dex-induced hypertension (122 +/- 5 and 136 +/- 3 mm Hg, respectively, P' =.057). Thymus weight was decreased in Dex-treated rats compared with saline treated rats (157 +/- 10 saline and 105 +/- 6 mg/100 g body weight Dex, P <.0005). Tempol affect neither thymus weight nor F(2)-isoprostane concentrations. CONCLUSIONS Chronic Dex treatment increased SBP and tended to increase oxidative stress shown as increased plasma F(2)-isoprostane concentrations. Tempol prevented and partially reversed Dex-induced hypertension, independent of improvement in systemic oxidative stress measured by F(2)-isoprostane concentrations.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008955 Models, Cardiovascular Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment. Cardiovascular Model,Cardiovascular Models,Model, Cardiovascular
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003497 Cyclic N-Oxides Heterocyclic compounds in which an oxygen is attached to a cyclic nitrogen. Heterocyclic N-Oxides,Cyclic N Oxides,Heterocyclic N Oxides,N Oxides, Cyclic,N-Oxides, Cyclic,N-Oxides, Heterocyclic,Oxides, Cyclic N
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
November 2007, American journal of hypertension,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
April 2006, American journal of hypertension,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
December 1985, Clinical science (London, England : 1979),
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
January 1994, Journal of applied toxicology : JAT,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
June 1987, Biokhimiia (Moscow, Russia),
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
November 1995, The American journal of physiology,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
January 2000, Blood pressure,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
December 2009, American journal of hypertension,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
August 1992, The American journal of physiology,
Yi Zhang, and Kevin D Croft, and Trevor A Mori, and Christopher G Schyvens, and Katja U S McKenzie, and Judith A Whitworth
January 2014, ISRN pharmacology,
Copied contents to your clipboard!